<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578564</url>
  </required_header>
  <id_info>
    <org_study_id>SOR-C13 01</org_study_id>
    <nct_id>NCT01578564</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel</brief_title>
  <official_title>Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soricimed Biopharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soricimed Biopharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of the drug SOR-C13&#xD;
      when given as an intravenous infusion in patients with ovarian cancer or other cancers known&#xD;
      to over express the TRPV6 calcium channel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Over 21 days from initial administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of SOR-C13</measure>
    <time_frame>Pre-treatment and up to 4 hours post-treatment on Study Days 1, 3, 8 and 10</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>SOR-C13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOR-C13</intervention_name>
    <description>Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period</description>
    <arm_group_label>SOR-C13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Males and females ≥ 18 years of age&#xD;
&#xD;
          -  Subjects with a histologic diagnosis of solid tumor cancers of epithelial origin.&#xD;
&#xD;
          -  Subjects with advanced refractory cancer for which standard curative or palliative&#xD;
             measures do not exist or are no longer effective. There is no limitation on the number&#xD;
             or types of prior therapy.&#xD;
&#xD;
          -  Subjects must have recovered from major infections and/or surgical procedures and, in&#xD;
             the opinion of the investigator, not have a significant active concurrent medical&#xD;
             illness precluding protocol treatment.&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) Performance Score ≤ 1.&#xD;
&#xD;
          -  Life expectancy of greater than 12 weeks.&#xD;
&#xD;
          -  Subjects must have adequate organ and marrow function as defined below:&#xD;
&#xD;
               1. hemoglobin ≥9.0 g/dL (≥5.6 mmol/L)&#xD;
&#xD;
               2. white blood cells ≥3,000/mm³(≥3×10⁹/L)&#xD;
&#xD;
               3. absolute neutrophil count ≥1,500/mm³ (≥1.5×10⁹/L)&#xD;
&#xD;
               4. platelets ≥100,000/μL (≥100×10⁹/L)&#xD;
&#xD;
               5. total bilirubin ≤1.5× upper limit of normal(ULN)&#xD;
&#xD;
               6. AST/ALT/AP ≤2.5× ULN (ALT/AST ≤5.0x ULN in case of documented liver metastases&#xD;
&#xD;
               7. creatinine ≤1.5× ULN&#xD;
&#xD;
               8. albumin ≥3.0 g/dL (≥30 g/L)&#xD;
&#xD;
               9. INR ≤1.4&#xD;
&#xD;
          -  Ability to understand and voluntarily sign the informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy&#xD;
             will not be allowed within either 30 days, or 5 half lives (whichever is longer) prior&#xD;
             to study drug administration.&#xD;
&#xD;
          -  History or clinical evidence of central nervous system (CNS) tumor involvement&#xD;
             (metastases) or other known clinically relevant CNS pathology (e.g., epilepsy,&#xD;
             seizure, paresis, aphasia, cerebellar disease, severe brain injury, psychosis).&#xD;
&#xD;
          -  Concurrent malignancy other than the solid tumor under investigation, requiring active&#xD;
             treatment.&#xD;
&#xD;
          -  History of clinically significant allergic reaction attributed to any injected&#xD;
             compound.&#xD;
&#xD;
          -  History of any of the following cardiovascular events or conditions within the past 6&#xD;
             months prior to enrolment: myocardial infarction, unstable angina, cerebrovascular&#xD;
             accident or transient ischemic attack, New York Heart Association Class ≥ II chronic&#xD;
             heart failure, hypokalemia, significant arrhythmia*; QTc interval &gt;430 msec or use of&#xD;
             drugs that prolong the QT interval at screening; family history of long QT syndrome.(*&#xD;
             Significant arrhythmias are defined as symptoms of syncope or severe palpitations&#xD;
             (palpitations requiring referral to cardiac monitoring), or ECG findings of&#xD;
             supraventricular tachycardia (including ventricular fibrillation) or ventricular&#xD;
             ectopy (ventricular premature depolarization).&#xD;
&#xD;
          -  Clinically significant and uncontrolled major medical condition(s) that places the&#xD;
             subject at an unacceptably high risk for toxicities. These include, but are not&#xD;
             limited to: active infections, symptomatic pulmonary disease, inadequate pulmonary&#xD;
             function, seizure disorder, psychiatric illness.&#xD;
&#xD;
          -  Current use of more than one antihypertensive medication.&#xD;
&#xD;
          -  For patients receiving antihypertensive medication:systolic blood pressure &lt; 120 mmHg&#xD;
             and/or diastolic blood pressure &lt; 70 mmHg at screening.&#xD;
&#xD;
          -  A known diagnosis of human immunodeficiency virus (HIV) infection or acquired immune&#xD;
             deficiency syndrome (AIDS), acute or chronic hepatitis B or hepatitis C infection, as&#xD;
             determined by medical history.&#xD;
&#xD;
          -  Major surgical procedure within 4 weeks prior to enrolment.&#xD;
&#xD;
          -  Lactating or pregnant female.&#xD;
&#xD;
          -  Females of childbearing potential and males not using adequate birth control.&#xD;
&#xD;
          -  Current treatment or treatment within 4 weeks of screening with bisphosphonates.&#xD;
&#xD;
          -  Screening serum calcium levels &lt; 2.20 mmol/L [8.8 mg/dL] (after correction for serum&#xD;
             albumin&#xD;
&#xD;
          -  History of acute pancreatitis within 12 months prior to screening&#xD;
&#xD;
          -  Known hypoparathyroidism, pseudohypoparathyroidism, or vitamin D deficiency, or&#xD;
             clinical evidence of other conditions known to associated with hypocalcemia,&#xD;
             including:, hypoalbuminemia, hyperphosphatemia, hypomagnesemia&#xD;
&#xD;
          -  Current treatment or treatment within 4 weeks of screening with drugs known to reduce&#xD;
             serum calcium levels, including: bisphosphonates, antiepileptic drugs, cinacalcet,&#xD;
             macrolide antibiotics (such as erythromycin, azithromycin), large doses of&#xD;
             corticosteroids (&gt;20 mg/day of prednisone or equivalent), or any IV use of&#xD;
             corticosteroids. In addition, long-term use (defined as ongoing use for ≥4 weeks) of&#xD;
             corticosteroids within 8 weeks of screening is prohibited&#xD;
&#xD;
          -  Any history of a venous thromboembolic event (VTE), including deep vein thrombosis&#xD;
             (DVT) or pulmonary embolism (PE)&#xD;
&#xD;
          -  Current treatment or treatment within 7 days of screening with a vitamin K antagonist,&#xD;
             such as warfarin. Patients who require anticoagulation due to their central line may&#xD;
             receive an alternative agent, such as low molecular weight heparin (LMWH).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toney T Ilenchuk, MS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Soricimed Biopharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230-1402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>TRPV6 Calcium channel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SOR-C13</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

